Adverse drug reactions to atezolizumab in combination with bevacizumab in hepatocellular carcinoma patients: an analysis of the food and drug administration adverse event reporting system database

Adverse drug reactions to atezolizumab in combination with bevacizumab in hepatocellular carcinoma patients: an analysis of the food and drug administration adverse event reporting system database

PurposeThe objective of the study is to systematically identify and evaluate the adverse drug reactions (ADRs) associated with the combination therapy of systematically and bevacizumab in patients with unresectable hepatocellular carcinoma (HCC).Patients and methodsData were extracted from the Food...

Full description

Saved in:
Bibliographic Details
Main Authors: Wanming He, Lihua Tong, Yanling Yuan, Xia Yang, Wen Yang, Xingxi Pan
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-02-01
Series:Frontiers in Pharmacology
Subjects:
anti-vascular endothelial growth factor
immune checkpoint inhibitor
programmed cell death protein 1
adverse events
hepatocellular carcinoma
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1448095/full
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items